Suven Life Sciences · NSE: SUVEN · BSE: 530239
Q4 FY19 results · Jan–Mar 2019
Suven Life Sciences reported revenue from operations of ₹0.00 crore and net profit of ₹0.00 crore for Q4 FY19 (Jan–Mar 2019), on a consolidated basis.
| Item | Q4 FY19 | Q4 FY18 | YoY | Q3 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 0.00 | — | — | — | — |
| Other income | 0.00 | — | — | — | — |
| Total income | 0.00 | — | — | — | — |
| Profit before tax | 0.00 | — | — | — | — |
| Net profit for the period | 0.00 | — | — | — | — |
| EPS, basic (₹) | 0.00 | — | — | — | — |
| Net margin (%) | — | — | — |
| Item | Q4 FY19 | Q4 FY18 | YoY | Q3 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 253.30 | — | — | 129.02 | +96.3% |
| Other income | 3.75 | — | — | 5.76 | −34.9% |
| Total income | 257.05 | — | — | 134.78 | +90.7% |
| Profit before tax | 102.01 | — | — | 35.22 | +189.6% |
| Net profit for the period | 67.98 | — | — | 25.23 | +169.4% |
| EPS, basic (₹) | 5.34 | — | — | 1.98 | +169.7% |
| Net margin (%) | 26.8 | — | 19.6 |
Consolidated
- Filed with BSE
- 25 May 2019, 16:33 IST
- Board meeting
- 25 May 2019
- Period
- 01 Jan 2019 to 31 Mar 2019
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 25 May 2019, 16:32 IST
- Board meeting
- 25 May 2019
- Period
- 01 Jan 2019 to 31 Mar 2019
- Review status
- Audited
- Source
- XBRL filing on BSE